NEW YORK (GenomeWeb News) – The US Federal Trade Commission announced on Tuesday it has reached an agreement with GeneLink and its former subsidiary foru International to settle charges of deceptive advertising claims made by the companies about their personalized nutritional supplements.

The settlement, which is not yet final, would also resolve allegations that GeneLink and foru engaged in "lax information security practices," the FTC said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.